Partner at Fasken
Marie Lafleur is a seasoned IP litigator. A senior partner at Fasken, she regularly appears before the Federal Court of Canada and Quebec’s provincial courts in proceedings under the Patented Medicines (Notice of Compliance) Regulations and litigation concerning pharmaceutical patent infringement and invalidity. Her expertise encompasses biologicals and biosimilars.
Ms Lafleur has represented numerous companies in proceedings to prevent the minister of health from issuing notices of compliance that would allow generic versions of patented drugs to be sold, including citalopram, escitalopram, doxylamine and pyridoxine, cyclosporine, omeprazole, diltiazem, divalproex and terazosin.
Ms Lafleur has also successfully filed numerous applications to add or remove patents from the Health Canada register. She was involved in many applications for judicial review of various decisions by provincial and federal health ministers.
Ms Lafleur’s expertise covers every extraordinary remedy, particularly seizures before judgment and injunctions, and she fully masters the range of alternative dispute resolution mechanisms available.
Ms Lafleur is a well-respected practitioner in the IP world. She is a regular speaker at thought leadership events and her expertise in the area has been recognised by the IAM Patent 1000, Best Lawyers in Canada, Managing Intellectual Property’s IP Stars and Who’s Who Legal: Canada.